170 related articles for article (PubMed ID: 15308606)
21. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients.
Bowden R; Chandrasekar P; White MH; Li X; Pietrelli L; Gurwith M; van Burik JA; Laverdiere M; Safrin S; Wingard JR
Clin Infect Dis; 2002 Aug; 35(4):359-66. PubMed ID: 12145716
[TBL] [Abstract][Full Text] [Related]
22. Liposomal amphotericin B prophylaxis of invasive mold infections in children post allogeneic stem cell transplantation.
Roman E; Osunkwo I; Militano O; Cooney E; van de Ven C; Cairo MS
Pediatr Blood Cancer; 2008 Feb; 50(2):325-30. PubMed ID: 17514732
[TBL] [Abstract][Full Text] [Related]
23. Twenty-four hour continuous infusion of amphotericin B for the treatment of suspected or proven fungal infection in haematology patients.
Hall P; Kennedy G; Morton J; Hill GR; Durrant S
Intern Med J; 2005 Jun; 35(6):374. PubMed ID: 15892774
[No Abstract] [Full Text] [Related]
24. Risk factors of amphotericin B toxicty in the nonneonatal pediatric population.
Dutta A; Palazzi DL
Pediatr Infect Dis J; 2012 Sep; 31(9):910-4. PubMed ID: 22581225
[TBL] [Abstract][Full Text] [Related]
25. Continuous infusion of amphotericin B: preliminary experience at Faculdade de Medicina da Fundação ABC.
Uehara RP; Sá VH; Koshimura ET; Prudente FV; Tucunduva LT; Gonçalves MS; Samano ES; del Giglio A
Sao Paulo Med J; 2005 Sep; 123(5):219-22. PubMed ID: 16358096
[TBL] [Abstract][Full Text] [Related]
26. Nephrotoxicity and other adverse events among inpatients receiving liposomal amphotericin B or amphotericin B lipid complex.
Wade RL; Chaudhari P; Natoli JL; Taylor RJ; Nathanson BH; Horn DL
Diagn Microbiol Infect Dis; 2013 Jul; 76(3):361-7. PubMed ID: 23774005
[TBL] [Abstract][Full Text] [Related]
27. Continuously infused amphotericin B deoxycholate for primary treatment of invasive fungal disease in acute myeloid leukaemia.
Rothenbühler C; Held U; Manz MG; Schanz U; Gerber B
Hematol Oncol; 2018 Apr; 36(2):471-480. PubMed ID: 29431860
[TBL] [Abstract][Full Text] [Related]
28. Intensive intravenous amphotericin B for prophylaxis of systemic fungal infections. Results of a prospective controlled pilot study in acute leukemia patients.
Karthaus M; Doellmann T; Klimasch T; Elser C; Rosenthal C; Ganser A; Heil G
Chemotherapy; 2000; 46(4):293-302. PubMed ID: 10859435
[TBL] [Abstract][Full Text] [Related]
29. Pre-medication practices and incidence of infusion-related reactions in patients receiving AMPHOTEC: data from the Patient Registry of Amphotericin B Cholesteryl Sulfate Complex for Injection Clinical Tolerability (PRoACT) registry.
Paterson DL; David K; Mrsic M; Cetkovsky P; Weng XH; Sterba J; Krivan G; Boskovic D; Lu M; Zhu LP;
J Antimicrob Chemother; 2008 Dec; 62(6):1392-400. PubMed ID: 18812423
[TBL] [Abstract][Full Text] [Related]
30. Treatment of invasive fungal infections in immunocompromised and transplant patients: AmBiLoad trial and other new data.
Muñoz P; Guinea J; Narbona MT; Bouza E
Int J Antimicrob Agents; 2008 Nov; 32 Suppl 2():S125-31. PubMed ID: 19013336
[TBL] [Abstract][Full Text] [Related]
31. Efficiency and safety of inhaled amphotericin B lipid complex (Abelcet) in the prophylaxis of invasive fungal infections following lung transplantation.
Borro JM; Solé A; de la Torre M; Pastor A; Fernandez R; Saura A; Delgado M; Monte E; Gonzalez D
Transplant Proc; 2008 Nov; 40(9):3090-3. PubMed ID: 19010204
[TBL] [Abstract][Full Text] [Related]
32. Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study.
Cordonnier C; Mohty M; Faucher C; Pautas C; Robin M; Vey N; Monchecourt F; Mahi L; Ribaud P
Int J Antimicrob Agents; 2008 Feb; 31(2):135-41. PubMed ID: 18162375
[TBL] [Abstract][Full Text] [Related]
33. Amphotericin B deoxycholate (d-AMB) use in cases with febrile neutropenia and fungal infections: lower toxicity with suitable premedication.
Oto OA; Paydas S; Disel U; Yavuz S; Seydaoglu G
Mycoses; 2007 Mar; 50(2):135-9. PubMed ID: 17305778
[TBL] [Abstract][Full Text] [Related]
34. In vivo distribution and therapeutic efficacy of a novel amphotericin B poly-aggregated formulation.
Espada R; Valdespina S; Dea MA; Molero G; Ballesteros MP; Bolás F; Torrado JJ
J Antimicrob Chemother; 2008 May; 61(5):1125-31. PubMed ID: 18285313
[TBL] [Abstract][Full Text] [Related]
35. Prevention of invasive fungal infections in liver transplant recipients: the role of prophylaxis with lipid formulations of amphotericin B in high-risk patients.
Fortún J; Martín-Davila P; Moreno S; Barcena R; de Vicente E; Honrubia A; García M; Nuño J; Candela A; Uriarte M; Pintado V
J Antimicrob Chemother; 2003 Nov; 52(5):813-9. PubMed ID: 14563893
[TBL] [Abstract][Full Text] [Related]
36. A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis.
Pappas PG; Chetchotisakd P; Larsen RA; Manosuthi W; Morris MI; Anekthananon T; Sungkanuparph S; Supparatpinyo K; Nolen TL; Zimmer LO; Kendrick AS; Johnson P; Sobel JD; Filler SG
Clin Infect Dis; 2009 Jun; 48(12):1775-83. PubMed ID: 19441980
[TBL] [Abstract][Full Text] [Related]
37. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial.
Rijnders BJ; Cornelissen JJ; Slobbe L; Becker MJ; Doorduijn JK; Hop WC; Ruijgrok EJ; Löwenberg B; Vulto A; Lugtenburg PJ; de Marie S
Clin Infect Dis; 2008 May; 46(9):1401-8. PubMed ID: 18419443
[TBL] [Abstract][Full Text] [Related]
38. Assessment of nephrotoxicity in patients receiving amphotericin B lipid complex: a pharmacosurveillance study in Spain.
Aguado JM; Lumbreras C; González-Vidal D;
Clin Microbiol Infect; 2004 Sep; 10(9):785-90. PubMed ID: 15355408
[TBL] [Abstract][Full Text] [Related]
39. Prospective phase II single-center study of the safety of a single very high dose of liposomal amphotericin B for antifungal prophylaxis in patients with acute myeloid leukemia.
Annino L; Chierichini A; Anaclerico B; Finolezzi E; Norata M; Cortese S; Cassetta MI; Fallani S; Novelli A; Girmenia C
Antimicrob Agents Chemother; 2013 Jun; 57(6):2596-602. PubMed ID: 23529741
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of alternative dosing regimens of poly-aggregated amphotericin B.
Espada R; Valdespina S; Molero G; Dea MA; Ballesteros MP; Torrado JJ
Int J Antimicrob Agents; 2008 Jul; 32(1):55-61. PubMed ID: 18534826
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
